Genotype–phenotype Correlation in Children with Pheochromocytoma and Paraganglioma
Nalini Shah, Vijaya Sarathi, M Sabaretnam
Citation Information :
Shah N, Sarathi V, Sabaretnam M. Genotype–phenotype Correlation in Children with Pheochromocytoma and Paraganglioma. World J Endoc Surg 2016; 8 (3):208-211.
Sarathi V, Sabaretnam M, Shah N. Genotype–phenotype Correlation in Children with Pheochromocytoma and Paraganglioma. World J Endoc Surg 2016;8(3):208-211.
International Symposium on Pheochromocytoma. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007 Feb;3(2):92-102.
A single pediatric center experience with 1025 children with hypertension. Acta Paediatr 1992 Mar;81(3):244-246.
Update on pediatric pheochromocytoma. Pediatr Nephrol 2009 May;24(5):943-950.
Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer 2013 Dec;21(1):17-25.
Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene 2016 Mar;35(9):1080-1089.
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 2015 Feb;11(2):101-111.
Models of parent-of-origin tumorigenesis in hereditary paraganglioma. Semin Cell Dev Biol 2015 Jul;43:117-124.
Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations. BMC Med Genet. 2014 Oct;15:111.
Pediatric and adolescent pheochromocytoma: clinical presentation and outcome of surgery. Indian Pediatr 2014 Apr;51(4):299-302.
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 2011 Mar;57(3):411-420.
Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 2012 Jul;48(11):1739-1749.
Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma Eur J Endocrinol 2016 Oct;175(4):311-323.
The clinical phenotype of SDHCassociated hereditary paraganglioma syndrome (PGL3). J Clin Endocrinol Metab 2014 Aug;99(8):E1482-E1486.
Penetrance and clinical features of pheochromocytoma in a six-generation family carrying a germlineTMEM127 mutation. J Clin Endocrinol Metab 2014 Nov;100(2):E308-E318.
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012 May;18(10):2828-2837.
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009 Dec;94(12):4757-4767.
Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 2015 Sep;21(17):3888-3895.
18F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas. Eur J Clin Invest 2014 Mar;44(3):325-332.
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009 Aug;10(8):764-771.
SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma. J Clin Endocrinol Metab 2014 Nov;100(2):E287-E291.
